UY38427A - Métodos y composiciones para terapia con células oculares - Google Patents
Métodos y composiciones para terapia con células ocularesInfo
- Publication number
- UY38427A UY38427A UY0001038427A UY38427A UY38427A UY 38427 A UY38427 A UY 38427A UY 0001038427 A UY0001038427 A UY 0001038427A UY 38427 A UY38427 A UY 38427A UY 38427 A UY38427 A UY 38427A
- Authority
- UY
- Uruguay
- Prior art keywords
- cells
- methods
- cell therapy
- ocular
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
- C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Abstract
La presente invención provee células oculares, genéticamente modificadas por un sistema CRISPR dirigido a la expresión de B2M para terapia celular ocular. La invención provee además métodos para generar una población expandida de células oculares genéticamente modificadas, por ejemplo, células madre limbares (LSC) o células endoteliales corneales (CEC), en donde las células se expanden con el uso de un inhibidor de LATS y la expresión de B2M en las células se ha reducido o eliminado. La presente invención además provee poblaciones celulares, preparaciones, usos y métodos de terapia que comprenden dichas células.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862750962P | 2018-10-26 | 2018-10-26 | |
US201962902639P | 2019-09-19 | 2019-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38427A true UY38427A (es) | 2020-05-29 |
Family
ID=68393038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038427A UY38427A (es) | 2018-10-26 | 2019-10-23 | Métodos y composiciones para terapia con células oculares |
Country Status (21)
Country | Link |
---|---|
US (1) | US20200131474A1 (es) |
EP (1) | EP3870289A1 (es) |
JP (1) | JP2022505658A (es) |
KR (1) | KR20210069075A (es) |
CN (1) | CN112969472A (es) |
AU (1) | AU2019365590A1 (es) |
CA (1) | CA3116512A1 (es) |
CL (1) | CL2021001034A1 (es) |
CO (1) | CO2021005289A2 (es) |
CR (1) | CR20210196A (es) |
CU (1) | CU20210033A7 (es) |
EC (1) | ECSP21028556A (es) |
IL (1) | IL282447A (es) |
JO (1) | JOP20210080A1 (es) |
MX (1) | MX2021004532A (es) |
PE (1) | PE20211114A1 (es) |
PH (1) | PH12021550761A1 (es) |
SG (1) | SG11202102615RA (es) |
TW (1) | TW202030324A (es) |
UY (1) | UY38427A (es) |
WO (1) | WO2020084580A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201992232A1 (ru) | 2017-03-22 | 2020-05-14 | Новартис Аг | Композиции и способы для иммуноонкологии |
JOP20190257A1 (ar) * | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
WO2021113515A1 (en) * | 2019-12-03 | 2021-06-10 | The Schepens Eye Research Institute, Inc. | Injectable hydrogels for cell delivery to the vitreous |
EP4142879A1 (en) * | 2020-04-27 | 2023-03-08 | Novartis AG | Methods and compositions for ocular cell therapy |
WO2022226020A2 (en) * | 2021-04-20 | 2022-10-27 | Walking Fish Therapeutics | Engineering b cell-based protein factories to treat serious diseases |
CA3225082A1 (en) * | 2021-08-27 | 2023-03-02 | Brian C. Thomas | Enzymes with ruvc domains |
CN116286905B (zh) * | 2023-05-11 | 2023-08-15 | 内蒙古大学 | 牛源化CRISPR/boCas9基因编辑系统、方法及应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2770497B2 (ja) | 1988-11-24 | 1998-07-02 | 吉富製薬株式会社 | トランス―4―アミノ(アルキル)―1―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途 |
ES2148179T3 (es) | 1991-09-06 | 2000-10-16 | Yoshitomi Pharmaceutical | Compuesto de 4-amino(alquil)ciclohexan-1-carboxamida y uso del mismo. |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US5989835A (en) | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
DK0956865T4 (da) | 1996-08-12 | 2010-11-22 | Mitsubishi Tanabe Pharma Corp | Medikamenter omfattende Rho-kinaseinhibitor |
JPH11130751A (ja) | 1997-10-30 | 1999-05-18 | Yoshitomi Pharmaceut Ind Ltd | アミド化合物およびそれらの酸付加塩の標識化合物 |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
JP4851003B2 (ja) | 2000-12-21 | 2012-01-11 | 田辺三菱製薬株式会社 | 肝臓障害に基づく疾患の予防・治療剤 |
US20030125344A1 (en) | 2001-03-23 | 2003-07-03 | Bayer Corporation | Rho-kinase inhibitors |
EP1383771A1 (en) | 2001-04-20 | 2004-01-28 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
WO2002100833A1 (fr) | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
US6642263B2 (en) | 2001-11-19 | 2003-11-04 | Iconix Pharmaceuticals Inc. | Modulators of Rho C activity |
WO2003059913A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
MXPA04007191A (es) | 2002-01-23 | 2005-03-31 | Bayer Pharmaceuticals Corp | Derivados de pirimidina como inhibidores de rho-quinasa. |
ATE381557T1 (de) | 2002-01-23 | 2008-01-15 | Bayer Pharmaceuticals Corp | Rho-kinase inhibitoren |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
AU2003220935A1 (en) | 2002-04-03 | 2003-10-13 | Sumitomo Pharmaceuticals Company, Limited. | Benzamide derivatives |
ES2273047T3 (es) | 2002-10-28 | 2007-05-01 | Bayer Healthcare Ag | Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa. |
ES2374272T3 (es) | 2003-06-19 | 2012-02-15 | Glaxosmithkline Llc | Derivados de 5-(acilamino)indazol como inhibidores de quinasas. |
EP1644365A2 (en) | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
CN1242058C (zh) * | 2004-04-09 | 2006-02-15 | 西北农林科技大学 | 表皮干细胞构建组织工程化角膜上皮植片的制备方法及其用途 |
RS64622B1 (sr) | 2012-05-25 | 2023-10-31 | Univ California | Metode i sastavi za modifikaciju ciljane dnk upravljenu pomoću rnk i za modulaciju transkripcije upravljanu rnk |
JP6670743B2 (ja) | 2013-05-29 | 2020-03-25 | セレクティスCellectis | Ii型crisprシステムにおける新規のコンパクトなcas9足場 |
US20160237455A1 (en) | 2013-09-27 | 2016-08-18 | Editas Medicine, Inc. | Crispr-related methods and compositions |
CN107075469A (zh) * | 2014-06-27 | 2017-08-18 | 加利福尼亚大学董事会 | 培养的哺乳动物角膜缘干细胞、其产生方法和其用途 |
WO2016011080A2 (en) | 2014-07-14 | 2016-01-21 | The Regents Of The University Of California | Crispr/cas transcriptional modulation |
US20180141992A1 (en) | 2014-11-06 | 2018-05-24 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
AU2016261600B2 (en) * | 2015-05-08 | 2021-09-23 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
AU2016362129A1 (en) | 2015-12-04 | 2018-06-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
AU2016374253B2 (en) | 2015-12-18 | 2021-10-21 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
WO2017143210A1 (en) | 2016-02-19 | 2017-08-24 | The General Hospital Corporation | Methods for generating universal and custom mhc/hla-compatible hematopoietic progenitor cells |
CA3027124A1 (en) | 2016-06-10 | 2017-12-14 | Umc Utrecht Holding B.V. | Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response |
AU2017336094A1 (en) | 2016-09-29 | 2019-04-18 | Immunitybio, Inc. | HLA class I-deficient NK-92 cells with decreased immunogenicity |
JP2020505025A (ja) * | 2017-01-13 | 2020-02-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫工学的な改変をした多能性細胞 |
JOP20190257A1 (ar) | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
CN115671398B (zh) * | 2022-11-22 | 2024-03-01 | 首都医科大学附属北京同仁医院 | 一种3d打印仿生角膜缘移植物及其制备方法和用途 |
-
2019
- 2019-10-23 UY UY0001038427A patent/UY38427A/es unknown
- 2019-10-24 TW TW108138491A patent/TW202030324A/zh unknown
- 2019-10-25 EP EP19795669.1A patent/EP3870289A1/en not_active Withdrawn
- 2019-10-25 AU AU2019365590A patent/AU2019365590A1/en not_active Abandoned
- 2019-10-25 US US16/663,722 patent/US20200131474A1/en not_active Abandoned
- 2019-10-25 CU CU2021000033A patent/CU20210033A7/es unknown
- 2019-10-25 CA CA3116512A patent/CA3116512A1/en active Pending
- 2019-10-25 MX MX2021004532A patent/MX2021004532A/es unknown
- 2019-10-25 WO PCT/IB2019/059162 patent/WO2020084580A1/en unknown
- 2019-10-25 JP JP2021522072A patent/JP2022505658A/ja active Pending
- 2019-10-25 JO JOP/2021/0080A patent/JOP20210080A1/ar unknown
- 2019-10-25 CR CR20210196A patent/CR20210196A/es unknown
- 2019-10-25 PE PE2021000558A patent/PE20211114A1/es unknown
- 2019-10-25 SG SG11202102615RA patent/SG11202102615RA/en unknown
- 2019-10-25 KR KR1020217012812A patent/KR20210069075A/ko not_active Application Discontinuation
- 2019-10-25 CN CN201980069687.5A patent/CN112969472A/zh active Pending
-
2021
- 2021-04-06 PH PH12021550761A patent/PH12021550761A1/en unknown
- 2021-04-19 IL IL282447A patent/IL282447A/en unknown
- 2021-04-22 CL CL2021001034A patent/CL2021001034A1/es unknown
- 2021-04-22 EC ECSENADI202128556A patent/ECSP21028556A/es unknown
- 2021-04-23 CO CONC2021/0005289A patent/CO2021005289A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210069075A (ko) | 2021-06-10 |
CL2021001034A1 (es) | 2021-11-19 |
IL282447A (en) | 2021-06-30 |
MX2021004532A (es) | 2021-07-16 |
SG11202102615RA (en) | 2021-05-28 |
CR20210196A (es) | 2021-07-27 |
AU2019365590A1 (en) | 2021-04-22 |
PE20211114A1 (es) | 2021-06-22 |
JOP20210080A1 (ar) | 2023-01-30 |
TW202030324A (zh) | 2020-08-16 |
EP3870289A1 (en) | 2021-09-01 |
ECSP21028556A (es) | 2021-05-31 |
WO2020084580A1 (en) | 2020-04-30 |
CU20210033A7 (es) | 2021-12-08 |
CA3116512A1 (en) | 2020-04-30 |
CO2021005289A2 (es) | 2021-05-10 |
PH12021550761A1 (en) | 2021-12-13 |
JP2022505658A (ja) | 2022-01-14 |
CN112969472A (zh) | 2021-06-15 |
US20200131474A1 (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP21028556A (es) | Métodos y composiciones para terapia con células oculares | |
MX2020005503A (es) | Metodos para activar, modificar y expandir linfocitos t gamma delta para el tratamiento del cancer y de neoplasias malignas relacionadas. | |
MX2020004830A (es) | Medios y metodo para preparar vectores virales y usos de los mismos. | |
WO2018202808A3 (en) | EXPANSION OF T GAMMA DELTA LYMPHOCYTES, ASSOCIATED COMPOSITIONS AND METHODS OF USE | |
AR086098A1 (es) | Composiciones plaguicidas | |
CY1117419T1 (el) | Εναιωρημα βλαστοκυτταρου | |
CU24495B1 (es) | Compuestos que expanden las células hematopoyéticas y método ex vivo para expandir las células hematopoyéticas | |
BR112017007770A2 (pt) | cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc. | |
BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
MX2019008872A (es) | Prevencion y tratamiento de da?o o enfermedad osea y cartilago. | |
ECSP20084373A (es) | Tiofencarboxamidas sustituidas y análogos de las mismas | |
CO2017002506A2 (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
BR112017006533A2 (pt) | usos de trealose em suspensões celulares | |
MX2020003833A (es) | Uso de composiciones que contienen streptomyces melanosporofaciens agl225 en el control de enfermedades de las plantas. | |
MX2020004063A (es) | Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados. | |
CO2022009119A2 (es) | Métodos para mejorar el cultivo celular con proteínas específicas de cada especie o específicas de cada género y las aplicaciones de los mismos | |
CL2021003328A1 (es) | Composiciones que comprenden iga secretora y probióticos. | |
AR069885A1 (es) | Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional | |
CL2018002900A1 (es) | Construcciones de adn para la fabricación de polipéptidos bioterapéuticos para su uso en vacunas animales y agentes terapéuticos. | |
AR110871A1 (es) | Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas | |
BR112023024434A2 (pt) | Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas | |
EA202191096A1 (ru) | Способы и композиции для терапии с применением клеток глаза | |
BR112018015527A2 (pt) | métodos para produção de vírus | |
CL2020003346A1 (es) | Métodos para tratar la pérdida de la audición y/o pérdida de la visión asociadas con clrn1 | |
CL2017001994A1 (es) | Extracto polifenolico natural y composición que lo contiene, y su uso como agente de biocontrol y método para controlar el deterioro del vino causada por la levadura brettanomyces bruxellensis en diferentes matrices del vino |